Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Fujian Medical University is the lead sponsor of 35 current clinical trials in our China register. 13 are recruiting patients now. The most common phase is Not applicable. The drugs named most often in its trials are Camrelizumab, Lenvatinib and Anlotinib. The most-studied condition is Gastric Cancer.

ClinicalTrials.gov trials by status

Recruiting1337%
Not yet open1337%
Active, closed39%
By invitation617%

Trials by phase

Not applicable1337%
Observational1029%
Phase 3411%
Phase 2411%
Phase 113%
Phase EARLY_PHASE113%
Phase 413%
Phase 1/213%

Clinical trials sponsored by Fujian Medical University

35 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
A Cohort Study on the Safety of Laparoscopic Resection of 5cm or Larger Gastric Gastrointestinal Stromal Tumors NCT05938309 · ClinicalTrials.gov ↗ · Gastrointestinal Stromal Tumors	Observational	Recruiting	2023-05	China
3D-4K-ICG Laparoscopic Gastrectomy for Gastric Cancer NCT06161207 · ClinicalTrials.gov ↗ · Gastric Cancer, Surgery	Phase 3	Recruiting	2023-01	China
Clinical Outcomes of Indocyanine Green Tracer Using in Laparoscopic Gastrectomy With Extended Lymphadenectomy Beyond D2 for Locally Advanced Gastric Cancer (FUGES-30) NCT06945718 · ClinicalTrials.gov ↗ · Gastric Cancer, Surgery	Observational	Recruiting	2025-05	China
Dyadic Personalized Home-Based Activity Program for Mild-to-Moderate Dementia Patients Post-Discharge NCT07081750 · ClinicalTrials.gov ↗ · Dementia	Not applicable	Recruiting	2025-07	China
Remote Ischemic Preconditioning for Aute Type A Aortic Dissection Surgery NCT07383909 · ClinicalTrials.gov ↗ · Aortic Dissection Type A	Not applicable	Recruiting	2026-03	China
Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer NCT07419932 · ClinicalTrials.gov ↗ · Thyroid Cancer, Thyroid Neoplasms	Observational	Recruiting	2025-12	China
Intraoperative Neuromuscular Monitoring and Its Impact on Pre- and Postoperative Acoustic Outcomes in Thyroid Surgery NCT06254859 · ClinicalTrials.gov ↗ · Thyroid Cancer, Thyroid Cancer, Papillary	Observational	Recruiting	2024-03	China
Clinical Outcomes of Indocyanine Green Tracer Using in Laparoscopic Gastrectomy With Lymph Node Dissection for Remnant Gastric Cancer NCT05618821 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 2	Recruiting	2022-06	China
A Study on the Safety and Efficacy of the Combination of Candenizumab, Lenvatinib, and SOX Regimen in the Treatment of HER2 Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Patients NCT06277024 · ClinicalTrials.gov ↗ · Overall Response Rate	Not applicable	Recruiting	2023-01	China
Comparison of Tumor Efficacy Safety in Laparoscopic Resection of Gastrointestinal Stromal Tumors Between Favorable and Unfavorable Site NCT03716089 · ClinicalTrials.gov ↗ · GIST of Stomach, Gastric Cancer, Surgery	Observational	Recruiting	2018-10	China
Quantitative Intra-operative Assessment of Parathyroid Perfusion Using Indocyanine Green (ICG) Fluorescence Imaging NCT07010341 · ClinicalTrials.gov ↗ · Thyroid Surgery	Observational	Recruiting	2025-05	China
Hybrid Endoscopic Hemithyroidectomy and Targeted Ablation for Bilateral Papillary Thyroid Carcinoma NCT07033572 · ClinicalTrials.gov ↗ · Thyroid Neoplasms, Carcinoma, Papillary	Not applicable	Recruiting	2018-06	China
A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma NCT06363825 · ClinicalTrials.gov ↗ · Advanced Hepatocellular Carcinoma Drug: Camrelizumab	Phase 2	Recruiting	2024-04	China
the Clinical Efficacy of Robotic and Laparoscopic Radical Total Gastrectomy in Locally Advanced Middle and Upper Gastric Cancer NCT05235932 · Gastric Cancer, Robotic Gastrectomy	Not applicable	Not yet open	2022-02	China
Clinical Efficacy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Immunotypes NCT05610332 · ClinicalTrials.gov ↗ · Locally Advanced Gastric Cancer Drug: Camrelizumab	Phase 3	Not yet open	2022-11	China
WHITE CAP: Intra-operative Parathyroid Tissue Sensor (PTS)-Guided Assessment of Parathyroid Viability and Surgical Decision-Making NCT07043010 · ClinicalTrials.gov ↗ · Hyperparathyroidism, Primary, Parathyroid Neoplasms, Parathyroid Adenoma	Not applicable	Not yet open	2025-07	China
Clinical Study of Universal CD19 CAR-γδ T Cell Infusion in the Treatment of Relapsed/Refractory Acute B Lymphoblastic Leukemia NCT07491263 · ClinicalTrials.gov ↗ · Relapsed/Refractory CD19-positive B-ALL Drugs: Cyclophosphamide, Fludarabine, QH103 Cell	Phase 1	Not yet open	2026-05	China
RET-US Study - Ultrasound-Based Prediction of RET Alterations and Lateral-Neck Metastasis in Thyroid Cancer NCT07042984 · ClinicalTrials.gov ↗ · Papillary Thyroid Carcinoma, Thyroid Neoplasms, RET Proto-Oncogene Mutation	Observational	Not yet open	2025-07	China
QL1706 Combined With Standard Therapy for Conversion Therapy of Synchronous Liver Metastases From Colon Cancer: a Multicenter, Single-arm, Exploratory Study NCT07649473 · ClinicalTrials.gov ↗ · Colon Cancer, Synchronous Liver Metastases Drug: Iparomlimab and Tuvonralimab	Phase 2	Not yet open	2026-08	China
Peri-operative BiPAP to Prevent Tracheostomy in High-Risk Bilateral Vocal-Cord Paralysis (BVCP) NCT07042971 · ClinicalTrials.gov ↗ · Vocal Cord Paralysis, Bilateral, Airway Obstruction, Postoperative, Thyroid Neoplasms	Not applicable	Not yet open	2025-07	China
Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study NCT07010393 · ClinicalTrials.gov ↗ · Thyroid Neoplasms Drugs: Anlotinib, Cabozantinib, Dabrafenib	Phase 4	Not yet open	2025-07	China
Computer Vision-Based Recognition of Parathyroid Glands and Recurrent Laryngeal Nerves in Endoscopic Surgery NCT07628543 · ClinicalTrials.gov ↗ · Thyroid Diseases, Thyroid Neoplasms	Observational	Not yet open	2026-06	China
A Prospective, Single-center, Randomized Controlled Clinical Study Evaluating the Efficacy and Safety of Hyperbaric Oxygen Therapy as an Adjunctive Treatment for Chronic Heart Failure NCT07311109 · ClinicalTrials.gov ↗ · Chronic Heart Failure With Reduced Ejection Fraction	Not applicable	Not yet open	2025-12	China
Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes NCT05524974 · ClinicalTrials.gov ↗ · Locally Advanced Gastric Cancer	Phase 2	Not yet open	2022-09	China
Total Robotic Versus Robotic Assisted Distal Gastrectomy for Gastric Cancer NCT04795063 · ClinicalTrials.gov ↗ · Gastric Cancer, Robotic Gastrectomy	Not applicable	Not yet open	2021-03	China
Clinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastric Cancer NCT07314203 · ClinicalTrials.gov ↗ · Gastric Cancer, Surgery Drug: Apatinib Mesylate	Phase 3	Not yet open	2026-12	China
Clinical Efficacy of Pucotenlimab Combined With Lenvatinib and SOX Versus SOX Alone in Patients With HER2-Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma NCT07356466 · ClinicalTrials.gov ↗ · Gastric (Stomach) Cancer Drugs: Lenvatinib, Oxaliplatin, Pucotenlimab	Phase EARLY_PHASE1	By invitation	2025-05	China
The Effectiveness of Different Therapeutic Jaw Position Determining Methods in Repositioning Splint Therapy for Temporomandibular Joint Disk Displacement Without Reduction：A Randomized Controlled Clinical Trial NCT07090772 · ClinicalTrials.gov ↗ · Temporomandibular Disorder (TMD)	Not applicable	By invitation	2025-07	China
Feasibility Study on the Application of Bionic Healing Abutments in Implant Impressions NCT07514585 · ClinicalTrials.gov ↗ · Dentition Defect, Healing Abutment	Observational	By invitation	2024-12	China
The Construction and Application of a Mobile Health Management Program for Elderly Depression Based on the Patterns of Cognitive Function Changes NCT06709027 · ClinicalTrials.gov ↗ · Patients With Depression in the Elderly	Not applicable	By invitation	2024-08	China
Effects of Omega-3 Fatty Acids on Acute Graft-versus-Host Disease After Allogeneic Stem Cell Transplantation. NCT07162688 · ClinicalTrials.gov ↗ · Graft-Versus-Host Disease(GVHD)	Phase 1/2	By invitation	2025-05	China
Social Participation Program for Older Adults in Nursing Homes NCT07079124 · ClinicalTrials.gov ↗ · Older Adults	Not applicable	By invitation	2025-07	China
Indocyanine Green Tracer Using in Laparoscopic Radical Gastrectomy for Locally Advanced Gastric Cancer NCT04593615 · ClinicalTrials.gov ↗ · Gastric Cancer, Surgery	Not applicable	Active, closed	2020-11	China
IGG Using in Laparoscopic Gastrectomy for Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy NCT04611997 · ClinicalTrials.gov ↗ · Gastric Cancer, Lymph Node Metastases Drug: Indocyanine Green	Phase 3	Active, closed	2020-11	China
Defining Benchmarks for Gastric Cancer Patients Underwent Minimal Invasive Gastrectomy NCT06938139 · ClinicalTrials.gov ↗ · Gastric Adenocarcinoma, Surgery, Laparoscopic	Observational	Active, closed	2025-03	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Fujian Medical University trials

20 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Conditions in Fujian Medical University trials

41 conditions

Gastric Cancer9Thyroid Neoplasms6Surgery5Robotic Gastrectomy2Locally Advanced Gastric Cancer2Thyroid Cancer2Hyperparathyroidism, Primary1Parathyroid Neoplasms1Parathyroid Adenoma1Hypocalcemia1Gastrointestinal Stromal Tumors1Relapsed/Refractory CD19-positive B-ALL1Gastric (Stomach) Cancer1Temporomandibular Disorder (TMD)1Papillary Thyroid Carcinoma1RET Proto-Oncogene Mutation1Lymphatic Metastasis1Dementia1Aortic Dissection Type A1Colon Cancer1Synchronous Liver Metastases1Vocal Cord Paralysis, Bilateral1Airway Obstruction, Postoperative1Sleep Apnea, Obstructive1

By trial register

Register	Trials	Recruiting
Clinical trials in China	35	13

A trial with sites in more than one country appears in each of those registers.

Other sponsors in Gastric Cancer

Sponsor	Trials
Nanfang Hospital, Southern Medical University	8
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	6
The First Affiliated Hospital with Nanjing Medical University	5
Chongqing Precision Biotech	4
RemeGen	3
Yunnan Cancer Hospital	3
TORL Biotherapeutics	2
Merus	2
Ono Pharmaceutical	2
Wuhan University	2

Sponsors with the most current trials registered for this condition.

Questions about Fujian Medical University trials

How many clinical trials does Fujian Medical University sponsor?

Fujian Medical University is the lead sponsor of 35 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Fujian Medical University trials recruiting?

Yes. 13 of its 35 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Fujian Medical University testing?

Its current trials name 20 drugs and biologicals as interventions. The most frequent are Camrelizumab (2), Lenvatinib (2), Anlotinib (1), Apatinib Mesylate (1) and Cabozantinib (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Fujian Medical University clinical trials